Conservation has never lacked ideas. Protected areas, payments for ecosystem services, community management, certification schemes, and public campaigns have all been promoted as solutions to ...

Abrocitinib shows sustained improvement in atopic dermatitis symptoms over two years with an acceptable safety profile.

SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...

Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...

Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today ...

CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory ...

Liberate Medical completes enrollment of its 250-patient PREVENT pivotal trial evaluating VentFree, a breakthrough ventilator weaning device for ICUs.

Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease after neoadjuvant ...

This afternoon, we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the Investors section of our ...

BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision ...

Diabetes mellitus is associated with worse RCC outcomes across all outcomes. Metformin use was associated with improved outcomes, but this association is likely substantially affected by time-related ...